Substantial savings opportunities exist by using lower-cost biologics for patients with plaque psoriasis, according to one ...

Clinical efficacy was evaluated using the Psoriasis Area and Severity Index (PASI), along with metabolic indicators such as ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

A RECENT study has highlighted key biological and clinical factors linked to resistance to biologic therapies in patients ...

Biologics targeting interleukin (IL)-12, IL-23, and IL-17 may have valuable safety benefits among older adults with psoriatic disease, as a lower rate of serious infection was observed among these ...

Sanofi’s development of an oral spin on Humira’s mechanism has hit a setback. | Sanofi’s development of an oral spin on ...

2003). It is also known that patients suffering from severe psoriasis often express dissatisfaction with their treatment (Gottlieb, 2004). Biologics have been an exciting development because they ...

Several characteristics, including BMI and Charlson Comorbidity Index, were associated with super response to biologics in patients with psoriasis.

Patients with generalized pustular psoriasis (GPP) experience frequent flares, and treatment alterations of off-label agents are frequently observed.

A panelist discusses how real-world evidence from a large cohort study (n = 31521) presented at AAD 2025 reveals notable ...

Obesity was linked to reduced long-term effectiveness of biologic therapy in patients with severe plaque psoriasis in a study, with dysregulated innate immune responses contributing to treatment ...

A clinical trial co-led by the Hospital for Special Surgery (HSS) has found that blocking inflammation with the drug ...